Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Dec 12;12(12):CD008827.
doi: 10.1002/14651858.CD008827.pub2.

Huperzine A for mild cognitive impairment

Jirong Yue  1 , Bi Rong Dong, Xiufang Lin, Ming Yang, Hong Mei Wu, Taixiang Wu
Affiliations

Huperzine A for mild cognitive impairment

Jirong Yue et al. Cochrane Database Syst Rev. .

Abstract

Background: Mild cognitive impairment (MCI) has been proposed as a condition of intermediate symptomatology between the cognitive changes of ageing and fully developed symptoms of dementia. Treatment in the stages of MCI may delay the deterioration of cognitive impairment and delay the progression to dementia. Currently, the treatments for Alzheimer's disease have been focused on increasing acetylcholine levels in the brain. However, these drugs have not been proven to be effective for MCI and have numerous side effects. Huperzine A may have some beneficial effects in MCI.

Objectives: To assess the clinical efficacy and safety of huperzine A for the treatment of patients with MCI.

Search methods: We searched ALOIS: the Cochrane Dementia and Cognitive Improvement Group's Specialized Register on 23 May 2011 using the terms: huperzine, ayapin, scoparon. ALOIS contains records of clinical trials identified from monthly searches of a number of major healthcare databases, numerous trial registries and grey literature sources. Additional searches were also performed separately in MEDLINE, EMBASE, PsycINFO, LILACS, clinicalTrials.gov, the ICTRP (WHO portal), CENTRAL (The Cochrane Library) and Web of Science with Conference Proceedings.The following Chinese databases were searched: The Chinese Biomedical Database, VIP Chinese Science and Technique Journals Database, China National Knowledge Infrastructure and The Chinese Clinical Trials Register. In addition, we handsearched 20 Chinese traditional medicine journals from between 1970 and 1989.

Selection criteria: Randomised, parallel-group, placebo-controlled trials comparing huperzine A with placebo in patients with MCI were eligible for inclusion.

Data collection and analysis: Two review authors independently assessed studies for their eligibility for inclusion.

Main results: No eligible trials were identified. In the absence of any suitable randomised placebo-controlled trials in this area, we were unable to perform a meta-analysis.

Authors' conclusions: The currently available evidence is insufficient to assess the potential for huperzine A in the treatment of MCI. Randomised double-blind placebo-controlled trials are needed.

PubMed Disclaimer

Conflict of interest statement

None.

Update of

References

References to studies excluded from this review

Cheng 2008 {published data only}
    1. Cheng X, Gu SW. Effectiveness of huperzine A in the treatment of mild cognitive impairment. Strait Pharmaceutical Journal 2008;20(2):50‐1.
Ding 2009 {published data only}
    1. Ding S‐J, Ni Y‐H, Li J‐S. Effectiveness of huperzine A, nimodipine and the combinative utilization to age associated memory impairment and influence of those to levels of plasma total antioxidant capacity and calcium of platelet [in Chinese]. Journal of Clinical Neurology 2009; Vol. 22, issue 2:130‐2.
Jiang 2009 {published data only}
    1. Jiang B, Meng X‐L, Shu G‐M, Yao C‐S, Chen Y‐M, Guo Y‐Q. Research of the patients with vascular cognitive impairment no dementia in terms of neuropsychology and the clinical study of huperzine A in the treatment. Chinese Journal of Clinical Neurosciences 2009;17(5):510‐4.
Lin 2008 {published data only}
    1. Lin G, Chen X. Preliminary analysis of huperzine A tablets for treatment of mild cognitive impairment in community. Chinese Journal of Integrative Medicine on Cardio‐/Cerebrovascular Disease 2008;6(9):1044‐5.
Ma 1998 {published data only}
    1. Ma YX, Zhu Y, Gu YD, Yu ZY, Yu SM, Ye YZ. Double‐blind trial of huperzine‐A (Hup) on cognitive impairment and dementia in 314 cases. Naunyn‐Schmiedebergs Archives of Pharmacology 1998; Vol. 358, issue 1:P35194.
Wang 2005 {published data only}
    1. Wang W, Wang L‐N, Zhou B, Zhang X‐H. Effect of huperzine A on memory function of patients with mild cognitive impairment. Zhongguo Linchuang Kangfu 2005; Vol. 9, issue 8:23‐5.
Xue 2005 {published data only}
    1. Xue S‐W, Ding J‐M, Zhong P, Liang K, An H‐Y, Bo Y. Impacts of huperzine A on the level of Fas, Apo2.7 and Bcl‐2 on the platelet membrane and the cognitive function in patients with Alzheimer disease. Chinese Journal of Clinical Rehabilitation 2005; Vol. 9, issue 9:188‐9.

Additional references

Albert 2011
    1. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia 2011;7:270‐9. - PMC - PubMed
Bai 2000
    1. Bai DL, Tang XC, He XC. Huperzine A: a potential therapeutic agent for treatment of Alzheimer's disease. Current Medicinal Chemistry 2000;7(3):355‐74. - PubMed
Birks 2000
    1. Birks J, Grimley Evans J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease. Cochrane Database of Systematic Reviews 2000, Issue 4. [DOI: 10.1002/14651858.CD005593] - DOI - PubMed
Birks 2006a
    1. Birks J, Flicker L. Donepezil for mild cognitive impairment. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD006104] - DOI - PubMed
Birks 2006b
    1. Birks J, Harvey R. Donepezil for dementia due to Alzheimer's disease. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD001190] - DOI - PubMed
Chen 2000
    1. Chen MJ, Gao ZX, Deng HY, Liu FG, Ma YX, Yu HZ, et al. Huperzine A capsules (upsilon) tablets in the treatment of Alzheimer disease: multicenter studies. Chinese Journal of New Drugs and Clinical Remedies 2000;19:10‐2.
Chow 2008
    1. Chow TW. Review: insufficient evidence on huperzine A for Alzheimer's. Evidence Based Mental Health 2008;11:112. - PubMed
Di Carlo 2000
    1. Carlo A, Baldereschi M, Amaducci L, Maggi S, Grigoletto F, Scarlato G, et al. Cognitive impairment without dementia in older people: prevalence, vascular risk factors, impact on disability. The Italian Longitudinal Study on Aging. Journal of the American Geriatrics Society 2000;48:775‐82. - PubMed
Ganguli 2004
    1. Ganguli M, Dodge HH, Shen C, DeKosky ST. Mild cognitive impairment, amnestic type: an epidemiologic study. Neurology 2004;13:115‐21. - PubMed
Gauthier 2006
    1. Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, et al. Mild cognitive impairment. Lancet 2006;367:1262‐70. - PubMed
Gracon 1996
    1. Gracon SI. Evaluation of tacrine hydrochloride (Cognex) in two parallel‐group studies. Acta Neurologica Scandinavica Supplementum 1996;165:114‐22. - PubMed
Graham 1997
    1. Graham JE, Rockwood K, Beattie BL, Eastwood R, Gauthier S, Tuokko H, et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet 1997;349:1793‐6. - PubMed
Ha 2011
    1. Ha GT, Wong RK, Zhang Y. Huperzine A as potential treatment of Alzheimer's disease: an assessment on chemistry, pharmacology, and clinical studies. Chemistry & Biodiversity 2011;8(7):1189‐204. - PubMed
Kozikowski 1999
    1. Kozikowski AP, Tückmantel W. Chemistry, pharmacology, and clinical efficacy of the Chinese nootropic agent huperzine A. Accounts of Chemical Research 1999;32(8):641‐50.
Kryscio 2006
    1. Kryscio RJ, Schmitt FA, Salazar JC, Mendiondo MS, Markesbery WR. Risk factors for transition from normal to mild cognitive impairment and dementia. Neurology 2006;66:828‐32. - PubMed
Larrieu 2002
    1. Larrieu S, Letenneur L, Orgogozo JM, Fabrigoule C, Amieva H, Carret N, et al. Incidence and outcome of mild cognitive impairment in a population‐based prospective cohort. Neurology 2002;59:1594‐9. - PubMed
Li 2008
    1. Li J, Wu HM, Zhou RL, Liu GJ, Dong BR. Huperzine A for Alzheimer's disease. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD005592.pub2] - DOI - PubMed
Liang 2004
    1. Liang YQ, Tang XC. Comparative effects of huperzine A, donepezil and rivastigmine on cortical acetylcholine level and acetylcholinesterase activity in rats. Neuroscience Letters 2004;361:56‐9. - PubMed
Liang 2007
    1. Liang YQ, Huang XT, Tang XC. Huperzine A reverses cholonergic and monoaminergic dysfunction induced by bilateral nucleus basalis magnocellularis injection of P‐amyloid peptide (1‐40) in rats. Cellular and Molecular Neurobiology 2007;28(1):1573‐6830. - PMC - PubMed
Lopez 2003
    1. Lopez OL, Jagust WJ, DeKosky ST, Becker JT, Fitzpatrick A, Dulberg C. Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1. Archives of Neurology 2003;60:1385‐9. - PubMed
Loy 2006
    1. Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD001747.pub3] - DOI - PMC - PubMed
Luis 2003
    1. Luis CA, Loewenstein DA, Acevedo A, Barker WW, Duara R. Mild cognitive impairment: directions for future research. Neurology 2003;61:438‐44. - PubMed
Manly 2005
    1. Manly JJ, Bell‐McGinty S, Tang MX, Schupf N, Stern Y, Mayeux R. Implementing diagnostic criteria and estimating frequency of mild cognitive impairment in an urban community. Archives of Neurology 2005;62:1739‐46. - PubMed
McShane 2006
    1. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD003154.pub5] - DOI - PubMed
Mount 2006
    1. Mount C, Downton C. Alzheimer's disease: progress or profit?. Nature Medicine 2006;12:780‐4. - PubMed
Peng 2006
    1. Peng Y, Jiang L, Lee DY, Schachter SC, Ma Z, Lemere CA. Effects of huperzine A on amyloid precursor protein processing and beta‐amyloid generation in human embryonic kidney 293 APP Swedish mutant cells. Journal of Neuroscience Research 2006;84:903‐11. - PubMed
Petersen 1999
    1. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E, et al. Mild cognitive impairment: clinical characterization and outcome?. Archives of Neurology 1999;56(3):303‐8. - PubMed
Petersen 2003
    1. Petersen RC. Mild cognitive impairment clinical trials. Nature Reviews Drug Discovery 2003;2:646‐53. - PubMed
Petersen 2004
    1. Petersen RC. Mild cognitive impairment as a diagnostic entity. Journal of Internal Medicine 2004;256:183‐94. - PubMed
Petersen 2011
    1. Petersen RC. Mild cognitive impairment. New England Journal of Medicine 2011;364(23):2227‐34. - PubMed
Rafii 2011
    1. Rafii MS, Walsh S, Little JT, Behan K, Reynolds B, Ward C, et al. A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology 2011;76(16):1389‐94. - PMC - PubMed
Ritchie 2000
    1. Ritchie K, Touchon J. Mild cognitive impairment: conceptual basis and current nosological status. Lancet 2000;355:225‐8. - PubMed
Ritchie 2001
    1. Ritchie K, Artero S, Touchon J. Classification criteria for mild cognitive impairment: a population‐based validation study. Neurology 2001;56:37‐42. - PubMed
Solfrizzi 2004
    1. Solfrizzi V, Panza F, Colacicco AM, D'Introno A, Capurso C, Torres F, et al. Vascular risk factors, incidence of MCI, and rates of progression to dementia. Neurology 2004;63:1882‐91. - PubMed
Terry 2011
    1. Terry Jr AV, Callahan PM, Hall B, Webster SJ. Alzheimer's disease and age‐related memory decline (preclinical). Pharmacology Biochemistry and Behavior 2011;99(2):190‐210. - PMC - PubMed
Visser 2005
    1. Visser PJ, Scheltens P, Verhey FR. Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease?. Journal of Neurology, Neurosurgery & Psychiatry 2005;76:1348‐54. - PMC - PubMed
Wang 1999
    1. Wang LJ, Ji WX, Weng QS, Yang JS. Clinical investigation of huperzine A in treating 36 cases with senile AD. Journal of Shanghai Medicine and Pharmacy 1999;20(1):16‐8.
Wang 2001a
    1. Wang R, Zhang HY, Tang XC. Huperzine A attenuates cognitive dysfunction and neuronal degeneration caused by beta‐amyloid protein‐(1‐40) in rat. European Journal Pharmacology 2001;421:149‐56. - PubMed
Wang 2001b
    1. Wang R, Xiao XQ, Tang XC. Huperzine A attenuates hydrogen peroxide‐induced apoptosis by regulating expression of apoptosisrelated genes in rat PC12 cells. Neuroreport 2001;12:2629‐34. - PubMed
Wang 2006
    1. Wang R, Yan H, Tang XC. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacologica Sinica 2006;27:1‐26. - PubMed
Whitehouse 2006
    1. Whitehouse P, Brodaty H. Mild cognitive impairment. Lancet 2006;367:1979. - PubMed
Winblad 2004
    1. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, et al. Mild cognitive impairment‐beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. Journal of Internal Medicine 2004;256:240‐6. - PubMed
Xiao 2000
    1. Xiao XQ, Wang R, Han YF, Tang XC. Protective effects of huperzine A on beta‐amyloid(25‐35) induced oxidative injury in rat pheochromocytoma cells. Neuroscience Letters 2000;286:155‐8. - PubMed
Xiao 2002
    1. Xiao XQ, Zhang HY, Tang XC. Huperzine A attenuates amyloid beta‐peptide fragment 25‐35‐induced apoptosis in rat cortical neurons via inhibiting reactive oxygen species formation and caspase‐3 activation. Journal of Neuroscience Research 2002;67:30‐6. - PubMed
Xu 1995
    1. Xu SS, Gao ZX, Weng Z, Du ZM, Xu WA, Yang JS, et al. Efficacy of tablet huperzine‐A on memory, cognition, and behavior in Alzheimer's disease. Acta Pharmacologica Sinica 1995;16(5):391‐5. - PubMed
Xu 1999
    1. Xu SS, Cai ZY, Qu ZW, Yang RM, Cai YL, Wang GQ, et al. Huperzine‐A in capsules and tablets for treating patients with Alzheimer disease. Acta Pharmacologica Sinica 1999;20(6):486‐90. - PubMed
Yan 2007
    1. Yan H, Zhang HY, Tang XC. Involvement of M1‐muscarinic acetylcholine receptors, protein kinase C and mitogen‐activated protein kinase in the effect of huperzine A on secretory amyloid precursor protein‐alpha. Neuroreport 2007;18:689‐92. - PubMed
Yue 2010
    1. Yue J, Dong BR, Lin X, Yang M, Wu HM, Wu T. Huperzine A for mild cognitive impairment. Cochrane Database of Systematic Reviews 2010, Issue 11. [DOI: 10.1002/14651858.CD008827] - DOI - PMC - PubMed
Zangara 2003
    1. Zangara A. The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer's disease. Pharmacology Biochemistry and Behavior 2003;75(3):675‐86. - PubMed
Zhang 2002
    1. Zhang HY, Liang YQ, Tang XC, He XC, Bai DL. Stereoselectivities of enantiomers of huperzine A in protection against beta‐amyloid(25–35)‐induced injury in PC12 and NG108‐15 cells and cholinesterase inhibition in mice. Neuroscience Letters 2002;317:143‐6. - PubMed
Zhang 2003
    1. Zhang HY, Tang XC. Huperzine A attenuates the neurotoxic effect of staurosporine in primary rat cortical neurons. Neuroscience Letters 2003;340:91‐4. - PubMed
Zhang 2004
    1. Zhang HY, Yan H, Tang XC. Huperzine A enhances the level of secretory amyloid precursor protein and protein kinase C‐alpha in intracerebroventricular beta‐amyloid‐(1‐40) infused rats and human embryonic kidney 293 Swedish mutant cells. Neuroscience Letters 2004;360:21‐4. - PubMed
Zhang 2006
    1. Zhang HY, Tang XC. Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease. Trends in Pharmacological Sciences 2006;27:619‐25. - PubMed
Zhang 2008
    1. Zhang HY, Zheng CY, Yan H, Wang ZF, Tang LL, Gao X, et al. Potential therapeutic targets of huperzine A for Alzheimer's disease and vascular dementia. Chemico‐Biological Interactions 2008;175:396‐402. - PubMed

Publication types

MeSH terms

LinkOut - more resources